Clinical Trials · NCT00099333
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 49
- Start date
- Feb 2004
- Locations
- 5 sites, United States
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16